New peripherally-inserted central catheter designed to help clinicians attain and sustain zero central line-associated bloodstream infections
Proven 99.99% colonization reduction1 of gram-positive and gram-negative bacteria and fungi
Provides intraluminal and extraluminal protection for at least 30 days
LIMERICK, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated announced today that is now offering for sale the company’s ArrowEVOLUTION™ PICC with Chlorag+ard ™ antimicrobial technology in the United States. ArrowEVOLUTION is the first chlorhexidine-treated peripherally inserted central catheter (PICC) that provides broad spectrum antimicrobial protection both intra and extraluminally.
“With ArrowEVOLUTION PICC, we have redesigned the PICC with patient safety and comfort in mind and have developed the first chlorhexidine-based technology designed specifically to protect PICC catheter surfaces for at least 30 days from the pathogens that cause central line associated bloodstream infections (CLABSIs),” commented Jeff Black, Chairman and Chief Executive Officer of Teleflex. “We are excited about bringing this new technology option to hospitals striving to improve outcomes and attain and sustain zero CLABSIs, a major contributor to healthcare-acquired infections.”
More than 200,000 patients in the United States each year develop a central line associated bloodstream infection, and as many as 20 percent of these cases result in death.2 Consistently following maximal barrier precautions is proven to dramatically reduce the incidence of CLABSI. (Mermel, et.al. and Raad, et.al.3). In addition, an antimicrobial coating can protect catheter surfaces where pathogens attach, complementing hospital efforts to prevent CLABSIs.
With the introduction of ArrowEVOLUTION, clinicians now have access to a pressure injectable, non-tapered PICC with a proven antimicrobial technology chemically bonded to the surface inside and out and available in an ergonomically designed Maximal Barrier Precautions Tray that supports adherence to widely accepted guidelines.
Enhanced patient safety and comfort
Product features and enhancements designed to support patient safety and comfort include a non-tapered design to reduce risk of vessel occlusion, the Arrow® Blue FlexTip® designed to minimize vessel trauma, clear visualization under fluoroscopy and x-ray and staggered exit sites to reduce the risk of incompatible medications mixing and forming precipitate.
Chlorag+ard – a powerful new antimicrobial technology
Internal and external surfaces of the ArrowEVOLUTION PICC are treated with Chlorag+ard, a chlorhexidine-based antimicrobial technology proven to offer 4 log reduction in colonization of gram-positive and gram-negative bacteria and fungi, including pathogens such as MRSA, VRE, Escherichia coli, Candida albicans, and Acinetobacter baumannii3 known to cause CLABSIs. The ArrowEVOLUTION PICC is designed to provide an initial burst of chlorhexidine immediately after insertion to protect the subcutaneous tract. Chlorag+ard continues to release chlorhexidine for at least 30 days, resulting in a 99.99% colonization reduction.1 With only 1 in 10,000 surviving organisms, Chlorag+ard is clearly a powerful new technology.
Maximal Barrier Precautions Tray supports adherence to guidelines
The ArrowEVOLUTION PICC Maximal Barrier Precautions Tray equips caregivers with 30 essential tools to follow guidelines recommended by leading organizations including Centers for Disease Control (CDC), Society for Healthcare Epidemiology of America (SHEA) and the Institute for Healthcare Improvement (IHI).
Arrowg+ard Family of Products
Through its Arrow brand, Teleflex is one of the leading global providers of vascular access technology with a commitment to helping healthcare providers prevent infections. First introduced 20 years ago and available for acute central venous catheters (CVCs), Arrowg+ard antimicrobial technology and Maximal Barrier Precautions Trays have played an important role in successful hospital initiatives to reduce CLABSIs in patients with central venous catheters. More information about ArrowEVOLUTION PICC and Chlorag+ard technology is available at arrowevolution.com.
About Teleflex Incorporated
Teleflex Incorporated (NYSE: TFX) is a global provider of medical technology products that enable healthcare providers to improve patient outcomes, protect against infections and support patient and provider safety. Teleflex, which employs approximately 12,800 people worldwide, also has niche businesses that serve segments of the aerospace and commercial markets with specialty engineered products. Additional information about Teleflex can be obtained from the company's website at www.teleflex.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Based on In vitro data – Data on File
Getting Started Kit: Preventing Central Line Infections. Institute for Healthcare Improvement. 2004, p.39
Grady, N.P., Alexander, M., Dellinger, E.P., Gerberding, J.L. , Heard, S.O., Maki, D.G., Masur, H., McCormick, R.D., Mermel, L.A., Pearson, M.L., Raad, I.I., Randolph, A., Weinstein, R.A., “Guidelines for the Prevention of Intravascular Catheter-Related Infections”, Centers for Disease Control, August 9, 2002, Vol. 51, No. RR-10, pp7-8.
Data on file. Teleflex Incorporated
Jake Elguicze, 610-948-2836
Vice President, Investor Relations
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Biotechnology Hospitals Infectious Diseases Medical Devices Medical Supplies